Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Gastroenterology. 2021 Sep 14;162(1):253–268.e13. doi: 10.1053/j.gastro.2021.09.017

Figure 5. Depletion of MUC5AC sensitizes PC cells to gemcitabine in vivo.

Figure 5.

(A) Experimental schema and treatment strategy for xenograft from FG-Scr and FG-Sh5AC cells. Line graph demonstrating temporal mean percentage change in tumor volume in gemcitabine treated groups compared to the respective control groups. (B) Pictorial and quantitative representation of xenograft tumor volumes at euthanasia. (C-D) Immunohistochemistry analysis and quantitative histoscores demonstrating the expression of MUC5AC, SLC1A5, SLC7A11, and cleaved PARP in FG-Scr and FG-Sh5AC tumors treated with gemcitabine. (E) Representative and (F) quantitative analysis of β-catenin nuclear foci in gemcitabine-treated FG-Scr and FG-Sh5AC tumors. For visualization of the β-catenin foci, Gemcitabine-treated FG-Scr tumor images are represented at higher magnification as depicted by the scale bars. (G) Luminescence-based metabolic flux assay to demonstrate glutamate enrichment in the vehicle and gemcitabine-treated FG-Scr and FG-Sh5AC tumors. * P value < .05, ** P value < .01, scale bars (unless otherwise mentioned): 400 microns, magnified images: 200 microns